CORTEXYME INC (CRTX) Stock Price, Quote, News and Overview
NASDAQ:CRTX - Nasdaq - US22053A1079 - Common Stock - Currency: USD
CRTX Quote, Performance and Key Statistics
1.95
+0.05 (+2.63%)
The current stock price of CRTX is 1.95 USD. In the past month the price decreased by -12.16%. In the past year, price decreased by -96.55%.
CRTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CRTX
Company Profile
Cortexyme, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2019-05-09. The company’s pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer, and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis’ role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer’s disease, among others. Its drug-targeting platform allows the Company to take small molecules, peptides, or large molecules and deliver them directly to the site of disease or injury. The firm's drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer's disease. Its COR588 is a second-generation small-molecule lysine-gingipain inhibitor.
Company Info
CORTEXYME INC
269 East Grand Ave
South San Francisco CALIFORNIA 94080 US
CEO: Casey C. Lynch
Employees: 55
Company Website: https://www.cortexyme.com/
Phone: 14159105717.0
CORTEXYME INC / CRTX FAQ
What is the stock price of CORTEXYME INC today?
The current stock price of CRTX is 1.95 USD. The price increased by 2.63% in the last trading session.
What is the ticker symbol for CORTEXYME INC stock?
The exchange symbol of CORTEXYME INC is CRTX and it is listed on the Nasdaq exchange.
On which exchange is CRTX stock listed?
CRTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CORTEXYME INC stock?
11 analysts have analysed CRTX and the average price target is 22.7 USD. This implies a price increase of 1063.85% is expected in the next year compared to the current price of 1.95. Check the CORTEXYME INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CORTEXYME INC worth?
CORTEXYME INC (CRTX) has a market capitalization of 58.79M USD. This makes CRTX a Micro Cap stock.
How many employees does CORTEXYME INC have?
CORTEXYME INC (CRTX) currently has 55 employees.
What are the support and resistance levels for CORTEXYME INC (CRTX) stock?
CORTEXYME INC (CRTX) has a resistance level at 1.96. Check the full technical report for a detailed analysis of CRTX support and resistance levels.
Should I buy CORTEXYME INC (CRTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRTX, evaluating the profitability, health, valuation and growth aspects
- CORTEXYME INC (CRTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CORTEXYME INC (CRTX) Sales and EPS estimates to see what analysts future expectations are.
- CORTEXYME INC (CRTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CORTEXYME INC (CRTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- CORTEXYME INC (CRTX) Stock Chart to make your own analysis
- CORTEXYME INC (CRTX) Latest news and press-releases to stay up to date.
Does CORTEXYME INC (CRTX) stock pay dividends?
CRTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of CORTEXYME INC (CRTX)?
CORTEXYME INC (CRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.97).
CRTX Technical Analysis
CRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRTX. CRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CRTX Financial Highlights
Over the last trailing twelve months CRTX reported a non-GAAP Earnings per Share(EPS) of -2.97. The EPS decreased by -6.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.21% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 45% to CRTX. The Buy consensus is the average rating of analysts ratings from 11 analysts.